Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:item
|
| gptkbp:activities |
inhibits vitamin K epoxide reductase
|
| gptkbp:appointed_by |
oral medication
doses adjusted based on INR |
| gptkbp:approves |
gptkb:1954
gptkb:FDA |
| gptkbp:brand |
gptkb:Coumadin
gptkb:Jantoven |
| gptkbp:caused_by |
gptkb:purple_toe_syndrome
skin necrosis |
| gptkbp:contraindication |
pregnancy
severe liver disease active bleeding |
| gptkbp:developed_by |
gptkb:Coumadin
|
| gptkbp:diet |
vitamin K intake
|
| https://www.w3.org/2000/01/rdf-schema#label |
Warfarin
|
| gptkbp:ingredients |
healthcare providers
|
| gptkbp:interacts_with |
antibiotics
antidepressants certain foods NSAI Ds |
| gptkbp:is_available_in |
tablets
liquid form |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_considered |
high-risk medication
|
| gptkbp:is_monitored_by |
INR levels
|
| gptkbp:is_part_of |
anticoagulation therapy
|
| gptkbp:is_subject_to |
drug interactions
food interactions |
| gptkbp:is_used_for |
preventing blood clots
|
| gptkbp:is_used_in |
gptkb:deep_vein_thrombosis
gptkb:atrial_fibrillation pulmonary embolism venous thromboembolism cardiac conditions stroke prevention post-surgical patients thrombosis prevention mechanical heart valves |
| gptkbp:lifespan |
20 to 60 hours
|
| gptkbp:metabolism |
CY P3 A4
CY P2 C9 |
| gptkbp:side_effect |
nausea
bruising bleeding hair loss |
| gptkbp:suitable_for |
patients with severe renal impairment
patients with liver disease patients with hyperthyroidism patients with severe hypertension patients with certain cancers patients with active bleeding disorders patients with certain genetic variants patients with hypothyroidism patients with peptic ulcer disease patients with recent surgery patients with uncontrolled diabetes |